United Kingdom (UK)
Recombinant monoclonal antibody to KRAS G12D mutant. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma D113.
UniProt Accession Number of Target Protein: P01116-2
Alternative Name(s) of Target: K-Ras; GTPase Kras; KRAS2; RASK2; K-Ras 2; Ki-Ras; c-K-ras; c-Ki-ras; ras p21 protein; p21 ras; D113-2-1
Immunogen: The original antibody was generated by immunizing mice with a synthetic dodecapeptide 'KLVVVGADGVGK'.
Specificity: This antibody binds the G12D mutant form of human KRAS protein. This ras protein binds GDP/GTP and possess intrinsic GTPase activity, that results in conversion of nucleotide guanosine triphosphate (GTP) into guanosine diphosphate (GDP). This protein plays an important role in many signal transduction pathways and regulation of cell proliferation. Somatic KRAS mutations are highly observed in leukemias, colorectal cancer, pancreatic cancer and lung cancer. KRAS mutation is G12D which is estimated to be present in up to 37% pancreatic cancers and over 12% of colorectal cancers.
Application Notes: The binding reactivity and epitope characterization of this antibody towards human KRAS G12D mutant was determined using ELISA (PMID: 9440050). This antibody can bind both the peptide 'KLVVVGADGVGK' conjugated BSA as well as KRAS G12D mutant in an ELISA.
Antibody first published in:
Wang et al. Epitopic characterization of the human wild-type and mutant ras proteins using membrane-bound peptides. J Pept Res. 1997 Dec;50(6):483-92. PMID:9440050
Note on publication:
Describes the epitope characterization of many anti-ras protein antibodies.